Annual report pursuant to Section 13 and 15(d)

Acquisition (Details Narrative)

v3.21.1
Acquisition (Details Narrative) - USD ($)
12 Months Ended
Oct. 18, 2019
Jul. 15, 2019
Jun. 30, 2019
Dec. 31, 2019
Cliam offset amount       $ 735,000
Expiration period of claim       Jan. 15, 2020
Payment settlement $ 6,024,489      
Repayments of debt 887,858      
Goodwill   $ 8,300,000    
Finite lived intangible assets   $ 7,300,000    
Finite lived intangible assets weighted-average amortization period   8 years 4 months 24 days    
Business transaction expenses   $ 2,500,000    
Trademarks [Member]        
Finite lived intangible assets weighted-average amortization period   10 years    
Customer Relationships [Member]        
Finite lived intangible assets weighted-average amortization period   8 years    
Indemnification Holdback [Member]        
Repayments of debt 735,000      
AR Holdback [Member]        
Repayments of debt $ 152,858      
CGI Bio Pharma [Member]        
Business combination consideration amount     $ 775,000  
Accounts receivable       $ 830,000
Asset Purchase Agreement [Member] | Inital Tranche [Member]        
Payment of preferred stock financing   $ 13,800,000    
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]        
Assets and assumed certain liabilities   23,500,000    
Proceeds from debt   7,692,300    
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member] | Base Purchase Price [Member]        
Assets and assumed certain liabilities   $ 1,980,000